Clinical trials: Parathyroid Disease
Osteoporosis
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with…
- Trial name
- NCT00479037
- Testing
- Full Length Parathyroid Hormone, PTH(1-84), Strontium Ranelate
- Where
- Denmark
- Volunteers
- 82 people
- Sponsor
- Nycomed
Hemorrhage
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
Considering the total number of thyroid procedures in Germany (100000 - 120000 cases per year), TachoSil® is a valuable tool to support surgical haemostasis, avoiding lymph leaks and support speech-nerve saving approaches.
- Trial name
- NCT00700141
- Where
- 132 sites in Germany
- Volunteers
- 482 people
- Sponsor
- Nycomed
Osteoporosis
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with…
- Trial name
- PEAK (NCT00365456)
- Testing
- Parathyroid Hormone (PTH), Risedronate
- Where
- Denmark
- Volunteers
- 407 people
- Sponsor
- Takeda
Hyperparathyroidism, Secondary
Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients
Patients with kidney failure on dialysis can be successfully transplanted. However, many of them do not attain a normal kidney function and/or present a slow deterioration of kidney function after transplantation.
- Trial name
- PAD (NCT00646282)
- Testing
- doxercalciferol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Secondary Hyperparathyroidism
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Planned therapy will be six months.
- Trial name
- NCT01401478
- Where
- 13 sites in Russia
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hypoparathyroidism
Use of NPSP558 in the Treatment of Hypoparathyroidism
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
- Trial name
- REPLACE (NCT00732615)
- Testing
- NPSP558
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 124 people
- Sponsor
- Shire
Post-Surgical Hypoparathyroidism
PTH-independent Effects of Encaleret
Background: Parathyroid glands in the neck make a hormone that keeps blood calcium levels stable. Sometimes these glands are damaged or removed during neck surgery.
- Trial name
- NCT05735015
- Testing
- encaleret
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Hypoparathyroidism, Hypocalcemia
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
This randomized crossover study will evaluate the safety, efficacy, and pharmacodynamics of synthetic human PTH 1-34 (PTH) delivered by an insulin pump (omnipod) compared with twice- daily subcutaneous injections.
- Conditions
- Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Trial name
- NCT00743782
- Testing
- Synthetic Human Parathyroid Hormone 1-34 pump
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Obesity, Insulin Resistance
Effect of Vitamin D Supplementation on Muscle Mass and Function
The study was designed to assess the effects of vitamin D supplementation during exercise training on body composition, muscle function, and glucose tolerance.
- Conditions
- Obesity, Insulin Resistance, Inflammation
- Trial name
- NCT01199926
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Purdue University
Secondary Hyperparathyroidism, Chronic Kidney Disease
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who…
- Trial name
- EVOLVE (NCT00345839)
- Testing
- Cinacalcet
- Volunteers
- 3,883 people
- Sponsor
- Amgen
Hyperparathyroidism, Primary
18F-Fluorocholine for the Detection of Parathyroid Adenomas
The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.
- Trial name
- NCT03764007
- Testing
- 18F-Fluorocholine, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Thomas Hope
Secondary Hyperparathyroidism Due to Renal Causes
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in…
- Trial name
- PARIDOINAL (NCT01939977)
- Testing
- Paricalcitol, Calcifediol
- Where
- 16 sites in Spain
- Volunteers
- 148 people
- Sponsor
- Fundación Senefro
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Failure, Secondary Hyperparathyroidism
Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product…
- Trial name
- NCT01081665
- Where
- 19 sites in Greece
- Volunteers
- 237 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in patients receiving…
- Trial name
- NCT01576146
- Testing
- Etelcalcetide
- Volunteers
- 30 people
- Sponsor
- KAI Pharmaceuticals
Chronic Kidney Failure, Secondary Hyperparathyroidism
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
- Trial name
- PROTECT (NCT01083186)
- Where
- 24 sites in Greece
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Hyperparathyroidism, Disorders of Parathyroid Gland
Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
It is difficulty for the treatment of secondary hyperparathyroidism in the chronic kidney disease (CKD) patients who had not succeeded medical therapy and could not get parathyroidectomy.
- Trial name
- NCT01640184
- Testing
- Parathyroidectomy, Active vitamin D, Ultrasonic ablation
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Dongliang Zhang, MD
Parathyroid Adenomas
High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma
This study aims to determine whether HIFU treatment is a safe and effective alternative to an operation to remove all or part of the affected gland.
- Trial name
- NCT01291498
- Testing
- High Intensity Focused Ultrasound
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Oxford University Hospitals NHS Trust
Exercise, Bone Resorption
Enhancing Skeletal Adaptations to PTH and Exercise
Exercise is essential for building and maintaining bone mass and strength, but current exercise recommendations for how to achieve this lack detail on the optimal exercise prescription.
- Conditions
- Exercise, Bone Resorption, Bone Formation
- Trial name
- ESkAPE (NCT05029128)
- Testing
- Endurance exercise intervention
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development